Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of Meltwater Percolation on Preservation of Organic Aerosol Tracers in Glacier Archives.

Environmental science & technology·2025
Same author

Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors.

Scientific reports·2022
Same author

Equation of state and thermodynamic properties for mixtures of <math></math> , <math></math> , <math></math> , and <math></math> from ambient up to 1000 K and 280 MPa.

The Journal of supercritical fluids·2019
Same author

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.

Cell death & disease·2015
Same author

Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.

British journal of pharmacology·2010
Same author

The VIZIER project: preparedness against pathogenic RNA viruses.

Antiviral research·2007

Related Experiment Video

Updated: Jul 14, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Computational inhibitor design against malaria plasmepsins.

S Bjelic1, M Nervall, H Gutiérrez-de-Terán

  • 1Department of Cell and Molecular Biology, Biomedical Center, Uppsala University, Box 596, SE-75124 Uppsala, Sweden.

Cellular and Molecular Life Sciences : CMLS
|June 23, 2007
PubMed
Summary

Plasmepsins, key malaria parasite enzymes, are promising drug targets. This review explores transition state mimetics and computational methods for developing effective plasmepsin inhibitors to combat malaria.

More Related Videos

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
09:13

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases

Published on: November 22, 2024

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
09:25

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum

Published on: September 18, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
09:13

Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases

Published on: November 22, 2024

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
09:25

CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum

Published on: September 18, 2018

Area of Science:

  • Biochemistry
  • Parasitology
  • Drug Discovery

Background:

  • Plasmepsins are essential aspartic proteases for the malaria parasite, degrading host hemoglobin for nutrition.
  • Inhibiting plasmepsins, alongside falcipains, presents a potent strategy for antimalarial drug development.

Purpose of the Study:

  • To review the mechanism of plasmepsins I-IV.
  • To explore the potential of transition state mimetics in developing antimalarial compounds.
  • To summarize inhibitor development against plasmepsin II and relevant structural data.

Main Methods:

  • Review of existing literature on plasmepsin mechanisms and inhibitor development.
  • Analysis of computational techniques, including homology modeling and molecular docking.
  • Detailed discussion of binding affinity prediction using the linear interaction energy (LIE) method.

Main Results:

  • Computational methods, particularly LIE, have shown high success in developing malarial plasmepsin inhibitors.
  • Homology modeling and molecular docking are valuable tools in current inhibitor design projects.
  • Combining computational methods with binding free energy calculations offers a robust approach for lead optimization.

Conclusions:

  • Plasmepsins represent a validated target for antimalarial drug development.
  • Transition state mimetics show promise for lead compound generation.
  • Integrated computational approaches significantly advance the design of effective plasmepsin inhibitors.